US Broker Ratings

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Unraveling a 133.80% Potential Upside in the Biotechnology Sector

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, commands attention with a substantial market capitalization of $3.56 billion. Specializing in RNA-targeted therapeutics and gene therapies, the..

Encompass Health Corporation (EHC): Stock Analysis Reveals 8.82% Upside Potential for Strategic Investors

Encompass Health Corporation (NYSE: EHC), a prominent player in the healthcare sector, is capturing the attention of savvy investors with its impressive stock performance and promising growth potential. Specializing in..

iRhythm Technologies (IRTC) Stock Analysis: Healthcare Innovator with Strong Buy Ratings Amidst Valuation Challenges

Investors navigating the healthcare sector’s dynamic landscape may find iRhythm Technologies, Inc. (NASDAQ: IRTC) an intriguing prospect. With a current market capitalization of $4.59 billion, iRhythm is a pioneering medical..

Glaukos Corporation (GKOS) Investor Outlook: Analyzing 25% Potential Upside Amid Strong Buy Ratings

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic pharmaceuticals and medical devices, is catching the eye of investors with its promising growth potential. The company, headquartered in Aliso Viejo, California,..

Takeda Pharmaceutical (TAK) Stock Analysis: Exploring a 12.61% Potential Upside

Takeda Pharmaceutical Company Limited (NYSE: TAK), a prominent player in the healthcare sector, stands out in the drug manufacturing industry with its strong global presence and diverse pharmaceutical offerings. Headquartered..

Insmed Incorporated (INSM) Stock Analysis: A Biotech Powerhouse with 11.48% Upside Potential

For investors keen on the biotechnology sector, Insmed Incorporated (INSM) offers an intriguing opportunity. With a robust market cap of $18.75 billion and an impressive array of advanced therapeutic developments,..

Labcorp Holdings Inc. (LH) Investor Outlook: Analyzing Growth Potential and Market Position

Labcorp Holdings Inc. (NYSE: LH) stands out as a key player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $21.86 billion, Labcorp..

TG Therapeutics, Inc. (TGTX): Analyst Consensus and Growth Potential in the Booming Biotech Sector

TG Therapeutics, Inc. (NASDAQ: TGTX) has emerged as a noteworthy player in the biotechnology landscape, boasting a market capitalization of $5.72 billion. This North Carolina-based biopharmaceutical company specializes in innovative..

Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unlocking 24% Potential Upside with Biotech Innovation

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is making waves in the biotechnology sector, drawing attention from investors with its innovative approach to drug delivery and a promising 24.12% potential upside. Headquartered..

Ascendis Pharma A/S (ASND) Stock Analysis: Exploring a 33.89% Potential Upside in Biotech Innovation

Ascendis Pharma A/S (NASDAQ: ASND), a Danish biopharmaceutical innovator, is capturing investor attention with its promising growth potential and cutting-edge therapeutic developments. Operating in the dynamic healthcare sector, Ascendis focuses..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: A Biotech Gem with 37% Upside Potential

Akero Therapeutics, Inc. (NASDAQ: AKRO) is sparking considerable interest in the biotechnology sector, thanks to an impressive potential upside of 37.18% based on analyst ratings. This South San Francisco-based company..

Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biopharma with a 111% Potential Upside

For investors with a keen eye on the biotechnology sector, Cytokinetics, Incorporated (NASDAQ: CYTK) presents a compelling case. This late-stage biopharmaceutical player is at the forefront of developing muscle activators..

ADMA Biologics Inc (ADMA) Stock Analysis: A 41.71% Potential Upside in the Biotech Sector

ADMA Biologics Inc (NASDAQ: ADMA), a prominent player in the biotechnology sector, has been catching the eye of investors with its impressive revenue growth and a significant potential upside. With..

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 28% Upside Potential with Strong Buy Ratings

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) stands as a formidable player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With a robust market capitalization of $12.31..

Molina Healthcare Inc (MOH) Stock Analysis: Exploring a 20.58% Potential Upside

Molina Healthcare Inc (NYSE: MOH) stands at a crucial juncture for investors, presenting a compelling opportunity with a potential upside of 20.58% as per analyst forecasts. A leader in the..

Grifols, S.A. (GRFS) Stock Analysis: Unlocking a 22% Upside Potential in the Healthcare Sector

Grifols, S.A. (GRFS) presents a compelling opportunity for investors seeking exposure in the healthcare sector, with a notable potential upside of 22.15%. As a prominent player in the plasma therapeutics..

BrightSpring Health Services (BTSG) Stock Analysis: Exploring a 28.87% Potential Upside

BrightSpring Health Services, Inc. (BTSG), a prominent player in the health information services industry, is making waves in the healthcare sector with its innovative approach to home and community-based services...

Genmab A/S (GMAB) Stock Analysis: Exploring a 30% Potential Upside in the Biotech Sector

For investors seeking opportunities in the dynamic biotechnology sector, Genmab A/S (NASDAQ: GMAB) presents a compelling case with its significant growth potential and robust pipeline of innovative cancer therapies. Headquartered..

Sanofi (SNY) Stock Analysis: Unveiling a 29% Potential Upside in the Healthcare Sector

Sanofi (SNY), a prominent player in the global healthcare market, deserves a close examination by investors looking for robust opportunities in the pharmaceutical sector. Headquartered in Paris, France, Sanofi is..

Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 120% Potential Upside for Investors

Avidity Biosciences, Inc. (NASDAQ: RNA), a pioneering player in the biotechnology sector, has captured the attention of investors with its innovative approach to RNA therapeutics, particularly through its proprietary antibody..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds